Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

CS1002 (ipilimumab biosimilar)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

CStone Pharma, Jiangsu Hengrui Pharma

Drug class:

CTLA4 inhibitor

Related drugs:

‹

›

MSI-H/dMMR	Melanoma	MSI-H/dMMR	Melanoma	ipilimumab biosimilar (CS1002) + CS1003 Sensitive: C3 – Early Trials ipilimumab biosimilar (CS1002) + CS1003 Sensitive : C3	ipilimumab biosimilar (CS1002) + CS1003 Sensitive: C3 – Early Trials ipilimumab biosimilar (CS1002) + CS1003 Sensitive : C3
MSI-H/dMMR	Hepatocellular Cancer	MSI-H/dMMR	Hepatocellular Cancer	ipilimumab biosimilar (CS1002) + CS1003 Sensitive: C3 – Early Trials ipilimumab biosimilar (CS1002) + CS1003 Sensitive : C3	ipilimumab biosimilar (CS1002) + CS1003 Sensitive: C3 – Early Trials ipilimumab biosimilar (CS1002) + CS1003 Sensitive : C3